QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 10 kg (about 22 pounds)
- You have received a stem cell transplant for a high-risk blood cancer and your blood cells have started growing back
- You are healthy enough for treatment (your doctor rates your overall health/ability to do daily activities as fair or better)
- If you could become pregnant, you agree to use birth control during the study
- You do not have moderate-to-severe graft-versus-host disease (a condition where transplanted cells attack your body)
- You have not received any cancer-fighting treatment in the past 3 weeks and will not receive any in the next 3 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests a new cell therapy called QH101 for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to standard treatment. It aims to see if this therapy can help control the disease.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
This trial tests a new drug (QLC2519) given alongside a standard chemotherapy regimen called VDC/IE for children and teens with sarcoma. The goal is to see if it can help treat their cancer more effectively.
This trial tests if a new medicine called QL0911 can help children with chronic ITP who haven't improved with standard treatments. It aims to raise platelet counts and reduce bleeding risk.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.